Testing the contributions of striatal dopamine loss to the genesis of parkinsonian signs

Neurobiology of Disease

Volumn 47, Issue 1, 2012, Pages 114-125

  Franco, Vanessa ^a   Turner, Robert S ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Akinesia; Bradykinesia; Cis flupenthixol; Macaque; Microinjection

Indexed keywords

DOPAMINE;

AKINESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINE RECEPTOR BLOCKING; DOPAMINE RELEASE; FEMALE; MACACA; MALE; MOTOR PERFORMANCE; MOVEMENT (PHYSIOLOGY); NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN SECRETION; RESPONSE TIME; REWARD; STRIATE CORTEX; TASK PERFORMANCE; VISUAL ACUITY;

ANIMALS; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINERGIC NEURONS; FEMALE; FLUPENTHIXOL; MACACA; MALE; MOVEMENT; NEOSTRIATUM; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; PUTAMEN; REACTION TIME;

EID: 84861234452     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.03.028     Document Type: Article

References (123)

1. Albin R.L., et al. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12:366-375.
2. Alexander G., et al. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
3. Alexander G.E., et al. Basal ganglia thalamo-cortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog. Brain Res. 1990, 85:119-146.
4. Alexander A.L., et al. Factors affecting drug distribution through infusion. PD Online Research 2009, The Michael J. Fox Foundation for Parkinson's Research, New York.
5. Amalric M., Koob G.F. Depletion of dopamine in the caudate nucleus but not in nucleus accumbens impairs reaction-time performance in rats. J. Neurosci. 1987, 7:2129-2134.
6. Aragona B.J., et al. Regional specificity in the real-time development of phasic dopamine transmission patterns during acquisition of a cue-cocaine association in rats. Eur. J. Neurosci. 2009, 30:1889-1899.
7. Arias P., Cudeiro J. Effects of rhythmic sensory stimulation (auditory, visual) on gait in Parkinson's disease patients. Exp. Brain Res. 2008, 186:589-601.
8. Arias P., Cudeiro J. Effect of rhythmic auditory stimulation on gait in Parkinsonian patients with and without freezing of gait. PLoS One 2010, 5:e9675.
9. Bachlin M., et al. Wearable assistant for Parkinson's disease patients with the freezing of gait symptom. IEEE Trans. Inf. Technol. Biomed. 2010, 14:436-446.
10. Bankiewicz K.S., et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. 2000, 164:2-14.
11. Beninger R.J., et al. Microinjections of flupenthixol into the caudate putamen of rats produce intrasession declines in food-rewarded operant responding. Pharmacol. Biochem. Behav. 1993, 45:343-350.
12. Bergman H., et al. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 1994, 72:507-520.
13. Bernheimer H., et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
14. Bronfeld M., et al. Spatial and temporal properties of tic-related neuronal activity in the cortico-basal ganglia loop. J. Neurosci. 2011, 31:8713-8721.
15. Chan F., et al. Deficits in saccadic eye-movement control in Parkinson's disease. Neuropsychologia 2005, 43:784-796.
16. Cooke J.D., et al. Increased dependence on visual information for movement control in patients with Parkinson's disease. Can. J. Neurol. Sci. 1978, 5:413-415.
17. Cooper J.A., et al. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991, 114:2095-2122.
18. Costall B., et al. Catalepsy and circling behaviour after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into the caudate-putamen, globus pallidus and substantia nigra of rat brain. Neuropharmacology 1972, 11:645-663.
19. Cunningham L.M., et al. A review of assistive technologies for people with Parkinson's disease. Technol. Health Care 2009, 17:269-279.
20. Cunnington R., et al. The preparation and execution of self-initiated and externally-triggered movement: a study of event-related fMRI. NeuroImage 2002, 15:373-385.
21. Damier P., et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122:1437-1448.
22. Debeir T., et al. Effect of intra-striatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus. Exp. Neurol. 2005, 193:444-454.
23. DeLong M.R., Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch. Neurol. 2007, 64:20-24.
24. Desmurget M., Turner R.S. Testing Basal Ganglia motor functions through reversible inactivations in the posterior internal globus pallidus. J. Neurophysiol. 2008, 99:1057-1076.
25. Dietz M.A., et al. Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov. Disord. 1990, 5:243-247.
26. Dubois B., Pillon B. Cognitive deficits in Parkinson's disease. J. Neurol. 1997, 244:2-8.
27. Eberling J.L., et al. Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys. Exp. Neurol. 2000, 165:342-346.
28. Ehringer H., Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klin. Wochenschr. 1960, 38:1236-1239.
29. Ellenbroek B., et al. Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats. Brain Res. 1985, 345:132-140.
30. Emborg M.E. Nonhuman primate models of Parkinson's disease. ILAR J. 2007, 48:339-355.
31. Espay A.J., et al. Impairments of speed and amplitude of movement in Parkinson's disease: a pilot study. Mov. Disord. 2009, 24:1001-1008.
32. Evarts E.V., et al. Reaction time in Parkinson's disease. Brain 1981, 104:167-186.
33. Fahn S. The freezing phenomenon in parkinsonism. Adv. Neurol. 1995, 67:53-63.
34. Flaherty A.W., Graybiel A.M. Corticostriatal transformations in the primate somatosensory sstem. Projections from physiologically mapped body-part representations. J. Neurophysiol. 1991, 66:1249-1263.
35. Flowers K.A. Visual "closed-loop" and "open-loop" characteristics of voluntary movement in patients with Parkinsonism and intention tremor. Brain 1976, 99:269-310.
36. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1996, 55:259-272.
37. Forsayeth J., et al. Gene therapy for Parkinson's disease: where are we now and where are we going?. Expert. Rev. Neurother. 2010, 10:1839-1845.
38. Francois C., et al. Calbindin D-28k as a marker for the associative cortical territory of the striatum in macaque. Brain Res. 1994, 633:331-336.
39. Francois C., et al. A stereotaxic atlas of the basal ganglia in macaques. Brain Res. Bull. 1996, 41:151-158.
40. Francois C., et al. Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys, and in Parkinson's disease patients. J. Comp. Neurol. 2000, 425:121-129.
41. Freeman A., et al. Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models. Ann. Neurol. 2001, 50:321-329.
42. Fudge J.L., et al. Amygdaloid inputs define a caudal component of the ventral striatum in primates. J. Comp. Neurol. 2004, 476:330-347.
43. Gallagher C.L., et al. A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease. Brain Imaging Behav. 2011, 5:203-211.
44. Gardinier J., et al. Interactions between lateralized choices of hand and target. Exp. Brain Res. 2006, 170:149-159.
45. Gerfen C.R. The neostriatal mosaic: Multiple levels of compartmental organization. Trends Neurosci. 1992, 15(4):133-139.
46. Goldman P.S., Nauta W.J.H. An intricately patterned prefronto-caudate projection in the rhesus monkey. J. Comp. Neurol. 1977, 171:369-386.
47. Hallett M., Khoshbin S. A physiological mechanism of bradykinesia. Brain 1980, 103:301-314.
48. Harman P.J., Carpenter M.B. Volumetric comparisons of the basal ganglia of various primates including man. J. Comp. Neurol. 1950, 93:125-137.
49. Hauber W., et al. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur. J. Neurosci. 2001, 14:1287-1293.
50. Hikosaka O., et al. Basal ganglia orient eyes to reward. J. Neurophysiol. 2006, 95:567-584.
51. Hoover J.E., Strick P.L. Multiple output channels in the basal ganglia. Science 1993, 259:819-821.
52. Hornykiewicz O., Kish S. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 1987, 45:19-34.
53. Hyttel J., et al. Receptor-binding profiles of neuroleptics. Psychopharmacology Suppl. 1985, 2:9-18.
54. Inase M., et al. Corticostriatal and corticosubthalamic input zones from the presupplementary motor area in the macaque monkey: comparison with the input zones from the supplementary motor area. Brain Res. 1999, 833:191-201.
55. Jan C., et al. Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients. Eur. J. Neurosci. 2000, 12:4525-4535.
56. Jankovic J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79:368-376.
57. Joel D., Weiner I. The organization of the basal ganglia-thalamocortical circuits: open interconnected rather than closed segregated. Neuroscience 1994, 63(2):363-379.
58. Jordan N., et al. A component analysis of the generation and release of isometric force in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1992, 55:572-576.
59. Kaur S., et al. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain. Eur. J. Pharmacol. 1997, 332:153-160.
60. Kelly R.M., Strick P.L. Macro-architecture of basal ganglia loops with the cerebral cortex: use of rabies virus to reveal multisynaptic circuits. Prog. Brain Res. 2004, 143:449-459.
61. Kimber T.E., et al. Voluntary movement after pallidotomy in severe Parkinson's disease. Brain 1999, 122:895-906.
62. Kish S.J., et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 1988, 318:876-880.
63. Kishore A., et al. Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesia. Mov. Disord. 2007, 22:328-333.
64. Krauze M.T., et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J. Neurosurg. 2005, 103:923-929.
65. Kravitz A.V., et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010, 466:622-626.
66. Kunzle H. Bilateral projections from precentral motor cortex to the putamen and other parts of the basal ganglia. An autoradiographic study in macaca fascicularis. Brain Res. 1975, 88:195-209.
67. Lees J., Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983, 106:257-270.
68. Lyons K.E., Pahwa R. Deep brain stimulation and tremor. Neurotherapeutics 2008, 5:331-338.
69. Mahler S.V., et al. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 2007, 32:2267-2278.
70. Malach R., Graybiel A.M. Mosaic architecture of the somatic sensory-recipient sector of the cat's striatum. J. Neurosci. 1986, 6:3436-3458.
71. Mallet N., et al. Disrupted dopamine transmission and the emergence of exaggerated beta oscillations in subthalamic nucleus and cerebral cortex. J. Neurosci. 2008, 28:4795-4806.
72. Marchese R., et al. The role of sensory cues in the rehabilitation of parkinsonian patients: a comparison of two physical therapy protocols. Mov. Disord. 2000, 15:879-883.
73. Martin R.F., Bowden D.M. A stereotaxic template atlas of the macaque brain for digital imaging and quantitative neuroanatomy. NeuroImage 1996, 4:119-150.
74. McCairn K.W., et al. The neurophysiological correlates of motor tics following focal striatal disinhibition. Brain 2009, 132:2125-2138.
75. McIntyre C.C., Hahn P.J. Network perspectives on the mechanisms of deep brain stimulation. Neurobiol. Dis. 2010, 38:329-337.
76. Meyer C.H. Akinesia in Parkinsonism. Relation between spontaneous movement (other than tremor) and voluntary movements made on command. J. Neurol. Neurosurg. Psychiatry 1982, 45:582-585.
77. Miocinovic S., et al. Stereotactic neurosurgical planning, recording, and visualization for deep brain stimulation in non-human primates. J. Neurosci. Methods 2007, 162:32-41.
78. Morris M.E., et al. Stride length regulation in Parkinson's disease. Normalization strategies and underlying mechanisms. Brain 1996, 119(Pt 2):551-568.
79. Morrish P.K., et al. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996, 119:585-591.
80. Nakamura K., Hikosaka O. Role of dopamine in the primate caudate nucleus in reward modulation of saccades. J. Neurosci. 2006, 26:5360-5369.
81. Nandhagopal R., et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009, 132:2970-2979.
82. Nieuwboer A., et al. A frequency and correlation analysis of motor deficits in Parkinson patients. Disabil. Rehabil. 1998, 20:142-150.
83. Nieuwboer A., et al. Upper limb movement interruptions are correlated to freezing of gait in Parkinson's disease. Eur. J. Neurosci. 2009, 29:1422-1430.
84. Oiwa Y., et al. Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease. J. Neurosurg. 2003, 98:136-144.
85. Oliveira R.M., et al. Micrographia in Parkinson's disease: the effect of providing external cues. J. Neurol. Neurosurg. Psychiatry 1997, 63:429-433.
86. Owen A.M., et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992, 115:1727-1751.
87. Parent A., et al. Calcium-binding proteins in primate basal ganglia. Neurosci. Res. 1996, 25:309-334.
88. Parkinson J. An essay on the shaking palsy 1817, Wittingham & Rowland, London.
89. Pavese N., et al. Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study. NeuroImage 2011, 56:1463-1468.
90. Pessiglione M., et al. Impairment of context-adapted movement selection in a primate model of presymptomatic Parkinson's disease. Brain 2003, 126:1392-1408.
91. Pifl C., et al. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropoyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 1991, 44:591-605.
92. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?. Mov. Disord. 2003, 18(Suppl. 7):S43-S51.
93. Praamstra P., et al. Reliance on external cues for movement initiation in Parkinson's disease. Evidence from movement-related potentials. Brain 1998, 121:167-177.
94. Redgrave P., et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat. Rev. Neurosci. 2010, 11:760-772.
95. Reimold M., et al. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl) 2007, 190:241-249.
96. Rommelfanger K.S., Wichmann T. Extrastriatal dopaminergic circuits of the Basal Ganglia. Front. Neuroanat. 2010, 4:139.
97. Saito R., et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res. 2004, 64:6858-6862.
98. Salamone J.D., et al. The role of brain dopamine in response initiation: effects of haloperidol and regionally specific dopamine depletions on the local rate of instrumental responding. Brain Res. 1993, 628:218-226.
99. Salamone J.D., et al. Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J. Pharmacol. Exp. Ther. 2003, 305:1-8.
100. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intra-striatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
101. Scatton B., et al. Dopamine deficiency in the cerebral cortex in Parkinson disease. Neurology 1982, 32:1039-1040.
102. Scatton B., et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 1983, 275:321-328.
103. Seibyl J.P., et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 1995, 38:589-598.
104. Selemon L.D., Goldman-Rakic P.S. Longitudinal topography and interdigitation of cortico-striatal projections in the rhesus monkey. J. Neurosci. 1985, 5:776-794.
105. Selikhova M., et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009, 132:2947-2957.
106. Shen W., et al. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321:848-851.
107. Shibasaki H., et al. Oculomotor abnormalities in Parkinson's disease. Arch. Neurol. 1979, 36:360-364.
108. Takada M., et al. Organization of inputs from cingulate motor areas to basal ganglia in macaque monkey. Eur. J. Neurosci. 2001, 14:1633-1650.
109. Temperli P., et al. How do parkinsonian signs return after discontinuation of subthalamic DBS?. Neurology 2003, 60:78-81.
110. Turner R., DeLong M. Corticostriatal activity in primary motor cortex of the macaque. J. Neurosci. 2000, 20:7096-7108.
111. van Donkelaar P., et al. Neuronal activity in the primate motor thalamus during visually triggered and internally generated limb movements. J. Neurophysiol. 1999, 82:934-945.
112. van Donkelaar P., et al. Temporary inactivation in the primate motor thalamus during visually triggered and internally generated limb movements. J. Neurophysiol. 2000, 83:2780-2790.
113. Vogelbaum M.A. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J. Neurooncol. 2005, 73:57-69.
114. Wakeman D.R., et al. Cell transplantation and gene therapy in Parkinson's disease. Mt. Sinai J. Med. 2011, 78:126-158.
115. Walter B.L., Vitek J.L. Surgical treatment for Parkinson's disease. Lancet Neurol. 2004, 3:719-728.
116. White O.B., et al. Ocular motor deficits in Parkinson's disease. I. The horizontal vestibulo-ocular reflex and its regulation. Brain 1983, 106:555-570.
117. Wichmann T., DeLong M.R. Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol. 1996, 6:751-758.
118. Wichmann T., et al. Milestones in research on the pathophysiology of Parkinson's disease. Mov. Disord. 2011, 26:1032-1041.
119. Worbe Y., et al. Behavioral and movement disorders induced by local inhibitory dysfunction in primate striatum. Cereb. Cortex 2009, 19:1844-1856.
120. Worbe Y., et al. Discontinuous long-train stimulation in the anterior striatum in monkeys induces abnormal behavioral states. Cereb. Cortex 2011, 21:2733-2741.
121. Yeterian E.H., Van Hoesen G.W. Cortico-striate projections in the Rhesus monkey: The organization of certain cortico-caudate connections. Brain Res. 1978, 139:43-63.
122. Yoshida Y., et al. Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen. Brain Res. 1994, 639:139-148.
123. Zetusky W.J., Jankovic J. Laterality and symptom association in Parkinson's disease. Arch. Neurol. 1985, 42:1132-1133.